Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …

Gastric neuroendocrine neoplasms (gNENs) display peculiar site-specific features among
all NENs. Their incidence and prevalence have been rising in the past few decades. gNENs …

Simple Summary Peptide receptor radionuclide therapy (PRRT) is a systemic treatment
consisting of the administration of a tumor-targeting radiopharmaceutical into the circulation …

According to the neuroendocrine tumour (NET) characteristics, 3 to 7 different treatment
options are available, corresponding to 6 to 5,040 theoretical different sequences. Even …

Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors, originating mostly
from the gastro-entero-pancreatic (GEP) tract followed by the lungs. Multidisciplinary …

Introduction: Carcinoid syndrome is the most frequent functional syndrome of
neuroendocrine neoplasia. It is characterized by flushing, diarrhea, wheezing, hypotension …

Peptide receptor radionuclide therapy (PRRT) today is a well-established treatment strategy
for patients with neuroendocrine tumors (NET). First performed already more than 30 years …

Most well-differentiated neuroendocrine tumors (NETs) express high levels of somatostatin
receptors, particularly subtypes 2 and 5. Somatostatin analogs (SSAs) bind to somatostatin …

Introduction Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a complex and
heterogenous family of solid malignancies that originate from neuroendocrine tissue in the …

Neuroendocrine neoplasms (NENs) comprise a beautifully complicated, exciting landscape
of histologies and clinical behaviors. However, the nuanced complexity of low-and high …